Nobivac Lepto, süstesuspensioon koertele
Nobivac Lepto, süstesuspensioon koertele
Not authorised
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated
Product identification
Medicine name:
Nobivac Lepto, süstesuspensioon koertele
Active substance:
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated
- Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain 820K, Inactivated1500.00antigen unit(s)1.00millilitre(s)
-
Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated1900.00antigen unit(s)1.00millilitre(s)
Pharmaceutical form:
-
Suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
- Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AB01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Surrendered
Authorised in:
-
Estonia
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- Intervet Nederland B.V.
Responsible authority:
- State Agency Of Medicines
Authorisation number:
- 1137
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it
in another language below.
Estonian (PDF)
Published on: 27/01/2022
How useful was this page?: